UniQure EBITDA Margin 2013-2022 | QURE

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for UniQure (QURE) over the last 10 years. The current EBITDA margin for UniQure as of December 31, 2022 is .
UniQure EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2022-09-30 $0.06B $-0.16B -260.66%
2022-06-30 $0.06B $-0.15B -233.87%
2022-03-31 $0.53B $0.31B 58.75%
2021-12-31 $0.52B $0.32B 60.69%
2021-09-30 $0.50B $0.31B 61.60%
2021-06-30 $0.50B $0.31B 62.20%
2021-03-31 $0.04B $-0.13B -328.95%
2020-12-31 $0.04B $-0.12B -302.63%
2020-09-30 $0.01B $-0.14B -2000.00%
2020-06-30 $0.01B $-0.13B -2166.67%
2020-03-31 $0.01B $-0.12B -2033.33%
2019-12-31 $0.01B $-0.12B -1642.86%
2019-09-30 $0.01B $-0.11B -1766.67%
2019-06-30 $0.01B $-0.09B -1150.00%
2019-03-31 $0.01B $-0.08B -933.33%
2018-12-31 $0.01B $-0.08B -690.91%
2018-09-30 $0.01B $-0.08B -625.00%
2018-06-30 $0.01B $-0.07B -600.00%
2018-03-31 $0.01B $-0.06B -484.62%
2017-12-31 $0.01B $-0.06B -484.62%
2017-09-30 $0.02B $-0.06B -300.00%
2017-06-30 $0.02B $-0.06B -262.50%
2017-03-31 $0.02B $-0.07B -291.30%
2016-12-31 $0.02B $-0.07B -279.17%
2016-09-30 $0.02B $-0.06B -289.47%
2016-06-30 $0.02B $-0.07B -443.75%
2016-03-31 $0.01B $-0.07B -500.00%
2015-12-31 $0.01B $-0.07B -600.00%
2015-09-30 $0.01B $-0.08B -877.78%
2015-06-30 $0.01B $-0.07B -1083.33%
2015-03-31 $0.01B $-0.06B -1160.00%
2014-12-31 $0.01B $-0.05B -900.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.946B $0.106B
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.172B 8.84
GSK (GSK) United Kingdom $75.535B 9.47
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.564B 19.57
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.289B 0.00
Biohaven (BHVN) United States $0.959B 0.00
Emergent Biosolutions (EBS) United States $0.444B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.111B 0.00
SQZ Biotechnologies (SQZ) United States $0.019B 0.00
Gelesis Holdings (GLS) United States $0.013B 0.00